Pharma companies are increasingly out-licensing clinical candidates from China to bolster their pipelines ahead of patent expirations. A GlobalData report highlights a surge in deals between Chinese biotechs and foreign pharma, with AstraZeneca leading in acquisitions. China now contributes to 20% of global drug development, with a focus on oncology, immunology, and metabolic candidates.

Regulatory reforms in China have facilitated a rise in out-licensing deals, but strained international relations pose a threat. The amended BIOSECURE Act could hinder Chinese companies from accessing US federal funds. Despite challenges, Chinese drug candidates continue to be out-licensed through innovative arrangements like NewCo deals.

China’s innovative landscape is increasingly recognized for best-in-class therapies, with a focus on oncology, immunology, and metabolic candidates. The country’s regulatory reforms and pilot programs have accelerated clinical trials and drug reviews. Chinese drugs are seen as a lifeline for global pharma amid the looming patent cliff, driving a surge in out-licensing deals.

Read more at Yahoo Finance: China’s drugs offer lifeline for global pharma as it peers over the patent cliff